Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Clinical Trial for Randomized, Blinded, Placebo-Controlled Evaluation of Safety, Tolerability and Preliminary Exploratory Immunogenicity of Recombinant Herpes Zoster Vaccine (CHO Cell) With Different Doses in Adults Aged 40 Years and Above

NCT07633197 is registered in ClinicalTrials.gov with Changchun BCHT Biotechnology Co. as lead sponsor.

NCT NCT07633197
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07633197 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Clinical Trial for Randomized, Blinded, Placebo-Controlled Evaluation of Safety, Tolerability and Preliminary Exploratory Immunogenicity of Recombinant Herpes Zoster Vaccine (CHO Cell) With Different Doses in Adults Aged 40 Years and Above
Lead sponsor
Changchun BCHT Biotechnology Co.
Phase
Phase 1
Overall status
Enrolling by invitation
Start date
May 28, 2026
Completion date
November 30, 2027
Enrollment
120 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

herpes